Sign up to save your podcasts
Or
Share Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen
On the latest BioCentury This Week podcast, BioCentury’s editors assess the fallout from the collapse of SVB and the sale of SVB UK to HSBC. BioCentury’s editors also discuss the proposed $43 billion acquisition of Seagen by Pfizer, takeaways from CDER Director Patrizia Cavazzoni’s conversation with Washington Editor Steve Usdin on The BioCentury Show and Editor in Chief Simone Fishburn’s call for pharma to put more women in the C-suite. This week’s podcast is sponsored by Jeito Capital.
Reach us by sending a text
View all episodes
By BioCentury
4.8
3232 ratings
On the latest BioCentury This Week podcast, BioCentury’s editors assess the fallout from the collapse of SVB and the sale of SVB UK to HSBC. BioCentury’s editors also discuss the proposed $43 billion acquisition of Seagen by Pfizer, takeaways from CDER Director Patrizia Cavazzoni’s conversation with Washington Editor Steve Usdin on The BioCentury Show and Editor in Chief Simone Fishburn’s call for pharma to put more women in the C-suite. This week’s podcast is sponsored by Jeito Capital.
Reach us by sending a text
More shows like BioCentury This Week
View all
Freakonomics Radio
32,333 Listeners
Bloomberg Intelligence
404 Listeners
Odd Lots
2,001 Listeners
Nature Podcast
762 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
340 Listeners
Making Sense
69 Listeners
Thoughts on the Market
1,312 Listeners
Biotech 2050 Podcast
62 Listeners
Business Of Biotech
86 Listeners
MIT Technology Review Narrated
265 Listeners
Biotech Hangout
19 Listeners
WSJ's Take On the Week
144 Listeners
The Top Line
16 Listeners
The BioCentury Show
11 Listeners